ImmunoPhotonics
Immunophotonics is dedicated to developing proprietary technology in the field of Interventional Immuno-Oncology™. The company's mission is to advance breakthrough drug discoveries and transform standard treatments into powerful immunotherapies, aiming to improve patient outcomes worldwide. Their vision involves a multimodal approach that elevates modern medicine, enabling routine treatments to provide enhanced results. The company actively collaborates with top universities and research institutions globally, and maintains a strong pipeline of patents supporting innovative off-the-shelf therapies for cancer treatment. Immunophotonics also emphasizes compliance with financial conflict of interest policies and maintains transparency through public posting and detailed procedures for managing conflicts, especially in federally funded projects.
Industries
Nr. of Employees
small (1-50)
ImmunoPhotonics
Columbia, Missouri, United States, North America
Patents
Products
Clinical-stage glycan polymer immunostimulant
A clinical-stage polymer material formulated for local injection into ablated or irradiated tumor tissue to bind liberated antigens, enhance antigen uptake by antigen-presenting cells, and promote systemic anti-tumor T-cell responses.
IP-001
IP-001 is the leading asset in Interventional Immuno-Oncology®, designed to be injected immediately following tumor ablation or radiation procedures to transform these into systemic immunotherapies by capturing liberated tumor antigens and activating antigen presenting cells.
N-dihydrogalactochitosan (GC)
N-dihydrogalactochitosan (GC) is a novel immune stimulant/adjuvant synthesized from chitosan and galactose, designed to enhance immune-stimulating properties for antitumor and antiviral immunities. It drives type I IFN activation and alternative STING pathways, enhancing dendritic cell activation and inflammatory responses within the tumor microenvironment.
Clinical-stage glycan polymer immunostimulant
A clinical-stage polymer material formulated for local injection into ablated or irradiated tumor tissue to bind liberated antigens, enhance antigen uptake by antigen-presenting cells, and promote systemic anti-tumor T-cell responses.
IP-001
IP-001 is the leading asset in Interventional Immuno-Oncology®, designed to be injected immediately following tumor ablation or radiation procedures to transform these into systemic immunotherapies by capturing liberated tumor antigens and activating antigen presenting cells.
N-dihydrogalactochitosan (GC)
N-dihydrogalactochitosan (GC) is a novel immune stimulant/adjuvant synthesized from chitosan and galactose, designed to enhance immune-stimulating properties for antitumor and antiviral immunities. It drives type I IFN activation and alternative STING pathways, enhancing dendritic cell activation and inflammatory responses within the tumor microenvironment.
Services
Design and support of investigator- and sponsor-led clinical studies combining local interventional procedures with locally delivered immunostimulants at academic medical centers.
Strategic collaborations with medical device manufacturers, clinical networks, and investors to advance combination interventional-immunotherapy programs toward clinical evaluation and commercialization.
Implementation and administration of financial conflict-of-interest policies for PHS-funded awards, including investigator training, disclosure workflows, external partner verification, report preparation, and record retention.
Design and support of investigator- and sponsor-led clinical studies combining local interventional procedures with locally delivered immunostimulants at academic medical centers.
Strategic collaborations with medical device manufacturers, clinical networks, and investors to advance combination interventional-immunotherapy programs toward clinical evaluation and commercialization.
Implementation and administration of financial conflict-of-interest policies for PHS-funded awards, including investigator training, disclosure workflows, external partner verification, report preparation, and record retention.
Expertise Areas
- Interventional immuno-oncology (integration of local tumor disruption with immunotherapy)
- Oncology clinical trial design and execution (early- and mid-stage)
- Polymer-based immunoadjuvant development
- Translational immunology and mechanism-of-action research
Key Technologies
- Polymer-based immunostimulants (glycan polymers)
- Intratumoral delivery techniques
- Thermal ablation and irreversible electroporation
- Antigen capture and presentation enhancement
News & Updates
Immunophotonics, Inc. has strengthened its leadership team with the appointment of Jacqueline Hess to its Board of Directors. With over 30 years of experience, Ms. Hess joins an already-robust slate of directors.
Immunophotonics is pioneering the field of Interventional Immunology-Oncology™, where a single injection of IP-001 is integrated into the clinical workflow to treat cancer.
Dr. Robert Martin has enrolled and treated the first patient in a groundbreaking Phase 2 study.
Tomas Hode, PhD, CIO & President will attend the AACR annual meeting in Chicago, IL.
A summary of the Phase 1b study concerning the combination of thermal treatments.
Networking and updates from the JPM Healthcare Conference.
Immunophotonics, Inc. has strengthened its leadership team with the appointment of Jacqueline Hess to its Board of Directors. With over 30 years of experience, Ms. Hess joins an already-robust slate of directors.
Immunophotonics is pioneering the field of Interventional Immunology-Oncology™, where a single injection of IP-001 is integrated into the clinical workflow to treat cancer.
Dr. Robert Martin has enrolled and treated the first patient in a groundbreaking Phase 2 study.
Tomas Hode, PhD, CIO & President will attend the AACR annual meeting in Chicago, IL.
A summary of the Phase 1b study concerning the combination of thermal treatments.
Networking and updates from the JPM Healthcare Conference.